Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Ipilimumab + Nivolumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ipilimumab Yervoy BMS-734016 CTLA4 Antibody 29 Immune Checkpoint Inhibitor 147 Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 mutant lung non-small cell carcinoma predicted - sensitive Ipilimumab + Nivolumab Clinical Study - Cohort Actionable In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). 31097096
ALK rearrange lung non-small cell carcinoma no benefit Ipilimumab + Nivolumab Guideline Actionable Immune checkpoint inhibitors including Keytruda (pembrolizumab), Tecentriq (atezolizumab), and the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) are not indicated for use as initial systemic therapy in non-small cell lung cancer patients harboring oncogenes, including ALK rearrangement (NCCN.org). detail...
MSH6 negative esophagus squamous cell carcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophagus squamous cell carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative stomach cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
BRAF V600X melanoma predicted - sensitive Ipilimumab + Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, melanoma patients harboring BRAF V600 mutations (V600E/K/R/D or V600_K601delinsE) treated with the combination of Yervoy (ipilimumab) and Opdivo (nivolumab) demonstrated significantly improved median progression-free survival (10.1 vs 5.2 months; P=0.0057) and median overall survival (not reached vs 16.9 months; P<0.0001) compared to patients without BRAF V600 mutations (PMID: 36130145). 36130145
MLH1 negative colorectal cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org). 36307056 detail...
MLH1 negative colorectal cancer sensitive Ipilimumab + Nivolumab FDA approved Actionable In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). detail... 29355075 detail...
MLH1 negative colorectal cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org). 37236086 detail...
MSH6 negative esophagus adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative ampulla of Vater adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative colon cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative small intestine adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative ampulla of Vater adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative colorectal cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org). 36307056 detail...
MSH6 negative colorectal cancer sensitive Ipilimumab + Nivolumab FDA approved Actionable In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). detail... detail... 29355075
MSH6 negative colorectal cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as a second-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) who progressed on first-line chemotherapy (PMID: 37236086; ESMO.org). detail... 37236086
MSH6 negative gastroesophageal junction adenocarcinoma sensitive Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). 35969830
MSH6 negative gastroesophageal junction adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative esophagus squamous cell carcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophagus squamous cell carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative gastric adenocarcinoma sensitive Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). 35969830
MLH1 negative gastroesophageal junction adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative gastroesophageal junction adenocarcinoma sensitive Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). 35969830
ATM inact mut Advanced Solid Tumor no benefit Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial (TAPUR), Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment did not meet predetermined efficacy criteria in patients with advanced solid tumors harboring ATM mutations, resulting in an objective response rate of 14% (4/29, 1 complete and 3 partial responses), a disease control rate of 24% (7/29), with stable disease of at least 16 weeks in 3 patients, a median progression-free survival of 9 weeks, and median overall survival of 28 weeks (PMID: 38039429; NCT02693535). 38039429
MLH1 negative gastric adenocarcinoma sensitive Ipilimumab + Nivolumab Phase II Actionable In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). 35969830
MLH1 negative esophagus adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative colon cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
BRAF act mut melanoma predicted - sensitive Ipilimumab + Nivolumab Clinical Study Actionable In a systematic review, an analysis of several clinical trials demonstrated Opdivo (nivolumab) plus Yervoy (ipilimumab) resulted in improved overall survival (OS) compared to BRAF plus MEK inhibitor in BRAF-mutant advanced melanoma patients when considering the entire study period, and analysis of the period beginning 12 months after treatment initiation demonstrated significantly greater OS and progression-free survival (PMID: 33556898; NCT01844505, NCT01584648, NCT01597908, NCT01909453, NCT01689519). 33556898
MSH6 negative rectum cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative stomach cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as first-line, second-line, or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative small intestine adenocarcinoma sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative rectum cancer sensitive Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05361720 Phase II Cabozantinib + Nivolumab Ipilimumab + Nivolumab Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Recruiting USA 0
NCT02872116 Phase III Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 21
NCT06097975 Phase I Ipilimumab + Nivolumab A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI) Not yet recruiting BEL 0
NCT03546686 Phase II Ipilimumab + Nivolumab Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer Recruiting USA 0
NCT04949113 Phase III Nivolumab Ipilimumab + Nivolumab Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) Active, not recruiting USA | NLD | AUS 0
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated USA 0
NCT03071406 Phase II Ipilimumab + Nivolumab Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Active, not recruiting USA 0
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Active, not recruiting USA 0
NCT04090710 Phase II Nivolumab Ipilimumab + Nivolumab SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) Active, not recruiting CAN | AUS 0
NCT03956680 Phase I Ipilimumab + Nivolumab BMS-986301 An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers Completed USA | CAN 0
NCT04620200 Phase II Ipilimumab + Nivolumab Nivolumab Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) Recruiting NLD 0
NCT04042753 Phase II Ipilimumab + Nivolumab Nivolumab Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Active, not recruiting USA 0
NCT03117309 Phase II Ipilimumab + Nivolumab Nivolumab Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Active, not recruiting USA 0
NCT05005273 Phase II Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUS 5
NCT03305445 Phase Ib/II Ipilimumab + Nivolumab Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Completed USA 0
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Active, not recruiting USA 0
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Active, not recruiting USA 0
NCT06295159 Phase I Nivolumab Nivolumab and relatlimab-rmbw Ipilimumab + Nivolumab Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Recruiting USA 0
NCT02714218 Phase III Ipilimumab + Nivolumab A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT04899921 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trigriluzole Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets Terminated USA 0
NCT05153304 Phase Ib/II Ipilimumab + Nivolumab A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers Not yet recruiting USA 0
NCT02599402 Phase III Ipilimumab + Nivolumab Nivolumab Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed ITA | GBR | FRA | DEU | BEL | AUT | AUS 5
NCT05341349 Phase I Ipilimumab + Nivolumab Pembrolizumab Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases Recruiting USA 0
NCT04088500 Phase II Ipilimumab + Nivolumab A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Terminated USA | CAN 0
NCT01940809 Phase II Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT02998528 Phase III Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Active, not recruiting USA | ITA | FRA | ESP | CAN 10
NCT03707457 Phase I Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Terminated USA 0
NCT02869789 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT04007588 Phase II Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Withdrawn USA 0
NCT03146650 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Active, not recruiting USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT04080804 Phase II Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Recruiting USA 0
NCT05004025 Phase I Ipilimumab + Nivolumab Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Recruiting USA 0
NCT04382664 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma Completed USA | GBR | BEL 1
NCT03026140 Phase II Ipilimumab + Nivolumab Celecoxib + Ipilimumab + Nivolumab Nivolumab + Relatlimab BMS-986253 + Nivolumab Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE) Recruiting NLD 0
NCT03307616 Phase II Ipilimumab + Nivolumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT05144529 Phase II Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101) Recruiting USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU 3
NCT04361162 Phase II Ipilimumab + Nivolumab Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer Active, not recruiting USA 0
NCT02210117 Phase II Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) Active, not recruiting USA 0
NCT02939300 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma Completed USA 0
NCT03048136 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn USA | DEU | CAN 2
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Active, not recruiting USA 1
NCT03437200 Phase II Nivolumab Ipilimumab + Nivolumab Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) Terminated FRA | ESP 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT03528408 Phase II Ipilimumab + Nivolumab Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Active, not recruiting USA 0
NCT03122522 Phase II Nivolumab Ipilimumab + Nivolumab A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy Active, not recruiting USA 0
NCT04131621 Phase II Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) Unknown status DEU 0
NCT04326257 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Active, not recruiting USA 0
NCT02350764 Phase II Ipilimumab + Nivolumab Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs Completed USA 0
NCT03101566 Phase II Cisplatin + Gemcitabine + Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Completed USA 0
NCT03262779 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Completed USA 0
NCT04300244 Phase II Ipilimumab + Nivolumab + UV1 Telomerase peptide vaccine Ipilimumab + Nivolumab Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) Active, not recruiting ESP | AUS 3
NCT06250335 Phase II Ipilimumab + Nivolumab Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients Recruiting USA 0
NCT03061539 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature Active, not recruiting GBR 0
NCT03670056 Phase II Ipilimumab + Nivolumab A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy Active, not recruiting USA 0
NCT03818685 Phase II Ipilimumab + Nivolumab Capecitabine Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) Active, not recruiting FRA 0
NCT03425292 Phase I Temozolomide Ipilimumab + Nivolumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Completed USA 0
NCT04495010 Phase II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) Withdrawn USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT04256213 Phase 0 Ipilimumab + Nivolumab COL Immunotherapy Before Radiochimio + Ipilimumab (COLIBRI) Active, not recruiting FRA 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT04250246 Phase II Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) Not yet recruiting ITA 0
NCT03597282 Phase I Ipilimumab + Nivolumab Nivolumab + Sotigalimab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC + Sotigalimab Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma Terminated USA 0
NCT05647265 Phase II Ipilimumab + Nivolumab Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma Recruiting USA 0
NCT04429321 Phase I Ipilimumab + Nivolumab Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary Terminated USA 0
NCT06365619 Phase II Ipilimumab + Nivolumab Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse) Not yet recruiting USA 0
NCT04500548 Phase I Nivolumab Ipilimumab + Nivolumab Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Withdrawn USA | CAN 0
NCT03233152 Phase I Ipilimumab + Nivolumab Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi) Unknown status BEL 0
NCT03377023 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Active, not recruiting USA 0
NCT03029780 Phase II Ipilimumab + Nivolumab An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma Completed USA | AUS 1
NCT03149159 Phase II Ipilimumab + Nivolumab Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Withdrawn USA 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN 2
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT02982954 Phase III Ipilimumab + Nivolumab A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) Completed USA 0
NCT02892734 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Terminated USA 0
NCT06097728 Phase III Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + MEDI5752 + Pemetrexed Disodium Ipilimumab + Nivolumab MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Terminated USA 0
NCT02408861 Phase I Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors Recruiting USA | AUS 0
NCT03068455 Phase III Nivolumab Ipilimumab Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT04938232 Phase II Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Active, not recruiting USA 0
NCT03799445 Phase II Ipilimumab + Nivolumab Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma Recruiting USA 0
NCT04013854 Phase II Ipilimumab + Nivolumab Nivolumab Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab Recruiting USA 0
NCT03789110 Phase II Ipilimumab + Nivolumab NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Active, not recruiting USA 0
NCT03873402 Phase III Nivolumab Ipilimumab + Nivolumab An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Active, not recruiting USA | ITA | FRA | ESP | AUT 9
NCT02186249 Phase III Ipilimumab + Nivolumab Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) No longer available USA | CAN 0
NCT03937219 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT03646617 Phase II Ipilimumab + Nivolumab Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma Recruiting USA 0
NCT02880020 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT03575793 Phase Ib/II Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Active, not recruiting USA 0
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT03469960 Phase III Ipilimumab + Nivolumab Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) Active, not recruiting FRA 0
NCT06240143 Phase Ib/II Ipilimumab + Nivolumab Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE) Not yet recruiting NLD 0
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma Terminated USA 0
NCT02659540 Phase I Ipilimumab + Nivolumab A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Completed USA 0
NCT05289193 Phase II Ipilimumab + Nivolumab CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma Recruiting USA 0
NCT03949153 Phase Ib/II Ipilimumab + Nivolumab Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN) Completed FRA 0
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Terminated USA 0
NCT03693846 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Terminated USA 0
NCT03463408 Phase I Ipilimumab + Nivolumab Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT05987332 Phase II Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT03075423 Phase II Sunitinib Ipilimumab + Nivolumab Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST) Active, not recruiting NLD | GBR | FRA | ESP | DEU | BEL 1
NCT05012254 Phase II Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) Recruiting ESP 0
NCT04039607 Phase III Lenvatinib Sorafenib Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02320058 Phase II Ipilimumab + Nivolumab A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) Completed USA 0
NCT02736123 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Withdrawn USA 0
NCT03520491 Phase II Ipilimumab + Nivolumab Nivolumab A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Recruiting USA 0
NCT05219435 Phase II Ipilimumab + Nivolumab Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) Recruiting ESP 0
NCT03600155 Phase I Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04008030 Phase III Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT03918252 Phase II Ipilimumab + Nivolumab Nivolumab Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Active, not recruiting USA 0
NCT02833233 Phase I Ipilimumab + Nivolumab A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer Active, not recruiting USA 0
NCT03443856 Phase II Ipilimumab + Nivolumab Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE) Active, not recruiting ITA | GBR | FRA | ESP | DEU 4
NCT06049576 Phase I Camu camu + Ipilimumab + Nivolumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Recruiting USA 0
NCT03274258 Phase II Ipilimumab + Nivolumab Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Active, not recruiting USA 0
NCT03355976 Phase II Ipilimumab + Nivolumab Nivolumab BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Active, not recruiting USA 0
NCT03651271 Phase II Ipilimumab + Nivolumab Nivolumab Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer Completed USA 0
NCT04465643 Phase I Ipilimumab + Nivolumab Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Recruiting USA 0
NCT05169957 Phase I Ipilimumab + Nivolumab Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) Recruiting USA 0
NCT04340193 Phase III Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT05928806 Phase II Balstilimab + Botensilimab Ipilimumab + Nivolumab Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) Recruiting USA 0
NCT02864251 Phase III Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) Completed USA | FRA | ESP | CAN 6
NCT03391869 Phase III Ipilimumab + Nivolumab Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT04575922 Phase II Ipilimumab + Nivolumab Nivolumab+Ipilimumab+RT in MSS mCRC Active, not recruiting USA 0
NCT05148546 Phase II Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) Recruiting NLD | GBR 0
NCT03604991 Phase II Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma Suspended USA 0
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting USA 0
NCT03823625 Phase II Ipilimumab + Nivolumab Carboplatin + Gemcitabine + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT) Unknown status ITA 0
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) Active, not recruiting USA 0
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed USA | CAN 0
NCT02919683 Phase II Nivolumab Ipilimumab + Nivolumab Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting USA 0
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Completed USA 0
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Completed USA 0
NCT03591731 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) Active, not recruiting FRA 0
NCT04730544 Phase II Ipilimumab + Nivolumab Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Recruiting FRA 0
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Terminated USA | NZL | ITA 0
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03682276 Phase Ib/II Ipilimumab + Nivolumab Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC) Recruiting GBR 0
NCT05199285 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Liver Cancer Recruiting USA 0
NCT04013542 Phase I Ipilimumab + Nivolumab Nivolumab Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Active, not recruiting USA 0
NCT04717154 Phase II Ipilimumab + Nivolumab Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) Active, not recruiting NLD 0
NCT05041062 Phase II Ipilimumab + Nivolumab A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Completed USA 0
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Active, not recruiting USA 0
NCT06364917 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC Not yet recruiting USA 0
NCT03001882 Phase II Ipilimumab + Nivolumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Completed USA | NLD | ITA | FRA | ESP | DEU | BEL 1
NCT03461952 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) Terminated USA | CAN 0
NCT05715229 Phase II Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT) Recruiting USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03162731 Phase I Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Completed USA 0
NCT02899299 Phase III Carboplatin + Cisplatin + Pemetrexed Disodium Ipilimumab + Nivolumab Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) Completed USA | NLD | ITA | GBR | FRA | DEU | BEL | AUS 13
NCT03104439 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting USA 0
NCT02823574 Phase II Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL 13
NCT03340129 Phase II Ipilimumab + Nivolumab Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) Recruiting AUS 1
NCT03724968 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression Terminated USA 0
NCT05704933 Phase I Ipilimumab + Nivolumab Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Active, not recruiting USA 0
NCT04145115 Phase II Ipilimumab + Nivolumab A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden Suspended USA 1
NCT02935634 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) Completed USA | NLD | ITA | DEU | CAN | AUS 3
NCT04511013 Phase II Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Recruiting USA 0
NCT02985957 Phase II Ipilimumab + Nivolumab A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 2
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 10
NCT02656706 Phase II Ipilimumab + Nivolumab BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial Active, not recruiting USA 0
NCT04751370 Phase II Ipilimumab + Nivolumab Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer Suspended USA 0
NCT05904080 Phase II Cabozantinib + Ipilimumab + Nivolumab Ipilimumab + Nivolumab Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Recruiting USA 0
NCT05310643 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) Recruiting FRA 0
NCT03335540 Phase I Linrodostat + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Completed USA 0
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT05116202 Phase Ib/II RO7247669 Atezolizumab + Tiragolumab Ipilimumab + Nivolumab RO7247669 + Tiragolumab A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) Completed USA | NLD | ITA | FRA | ESP | AUS 0
NCT02978443 Phase II Ipilimumab + Nivolumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Terminated USA 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 3
NCT05327686 Phase II Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab Ipilimumab + Nivolumab Avelumab + Axitinib Cabozantinib + Nivolumab Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) Recruiting USA 0
NCT04967196 Phase I Ipilimumab + Nivolumab Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma Active, not recruiting USA 0
NCT03815890 Phase II Nivolumab Ipilimumab + Nivolumab Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI) Recruiting NLD 0
NCT04006262 Phase II Ipilimumab + Nivolumab Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA) Recruiting FRA 0
NCT03138512 Phase III Ipilimumab + Nivolumab A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT06410534 Phase II Nivolumab Ipilimumab + Nivolumab A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer Not yet recruiting USA 0
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT05779423 Phase II Ipilimumab + Nivolumab Cryoablation+Ipilimumab+Nivolumab in Melanoma Recruiting USA 0
NCT03719131 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Active, not recruiting USA 0
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Completed USA 0
NCT04026412 Phase III Nivolumab Ipilimumab + Nivolumab Durvalumab A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT04462406 Phase II Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Recruiting USA 0
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Active, not recruiting USA 0
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT03367715 Phase II Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Completed USA 0
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT04323046 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Recruiting USA | AUS 2
NCT03223155 Phase I Ipilimumab + Nivolumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Completed USA | NLD | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT02659059 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Completed USA | CAN 0
NCT05302921 Phase II Ipilimumab + Nivolumab Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Active, not recruiting USA 0
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting USA | CAN 0
NCT03246958 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab in Thyroid Cancer Active, not recruiting USA 0
NCT05077280 Phase II Ipilimumab + Nivolumab A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Recruiting USA 0
NCT03425331 Phase II Ipilimumab + Nivolumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Suspended USA 0
NCT04966676 Phase II Ipilimumab + Nivolumab Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) Recruiting CAN 0
NCT03668119 Phase II Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT03241186 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Active, not recruiting USA 0
NCT03203473 Phase II Nivolumab Ipilimumab + Nivolumab Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Active, not recruiting USA 0
NCT04606316 Phase I Nivolumab Ipilimumab + Nivolumab Surgical Nivolumab And Ipilimumab For Recurrent GBM Active, not recruiting USA 0
NCT03036098 Phase III Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 22
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT03143153 Phase III Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | AUT | AUS 19
NCT02696993 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT04118166 Phase II Ipilimumab + Nivolumab Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma Completed USA 0
NCT03521830 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Recruiting USA 0
NCT03083691 Phase II Ipilimumab + Nivolumab BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Completed DEU 0
NCT03776487 Phase Ib/II Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Active, not recruiting USA 0
NCT05836571 Phase II Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Suspended USA | CAN 0
NCT05200988 Phase II Mitomycin C Ipilimumab + Nivolumab Capecitabine Fluorouracil Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade) Active, not recruiting NLD 0
NCT03220009 Phase II Ipilimumab + Nivolumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn USA 0
NCT02970981 Phase II Ipilimumab + Nivolumab Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma Completed USA 0
NCT02601014 Phase II Ipilimumab + Nivolumab Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Completed USA 0
NCT02857569 Phase Ib/II Ipilimumab + Nivolumab A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT) Completed FRA 0
NCT05112601 Phase II Ipilimumab + Nivolumab Nivolumab Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Recruiting USA 0
NCT03829111 Phase I Ipilimumab + Nivolumab CBM588 + Ipilimumab + Nivolumab CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer Active, not recruiting USA 0
NCT03604978 Phase Ib/II Ipilimumab + Nivolumab Nivolumab Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma Recruiting USA 0
NCT03406247 Phase II Ipilimumab + Nivolumab Nivolumab Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) Recruiting FRA 0
NCT04396860 Phase II Temozolomide Ipilimumab + Nivolumab Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Active, not recruiting USA 0
NCT03065179 Phase II Ipilimumab + Nivolumab Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients Completed USA 0
NCT04933903 Phase II Ipilimumab + Nivolumab BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab Recruiting USA 0
NCT03043599 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Completed USA 0
NCT03033576 Phase II Ipilimumab Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT02231749 Phase III Ipilimumab + Nivolumab Sunitinib Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT06364631 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab CARE1 Pragmatic Clinical Trial (CARE1) Recruiting FRA 0
NCT03903640 Phase II Ipilimumab + Nivolumab Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis Terminated USA 0
NCT03126461 Phase II Ipilimumab + Nivolumab SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients Withdrawn USA 0
NCT05926960 Phase II Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE) Recruiting ITA | GBR | ESP | DEU 3
NCT03749460 Phase Ib/II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Completed USA 0
NCT04823403 Phase I Ipilimumab + Nivolumab Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV) Recruiting FRA 0
NCT02996110 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) Completed USA | ITA | CAN | AUT | AUS 1


Additional content available in CKB BOOST